News Image

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Provided By PR Newswire

Last update: Oct 30, 2024

NEW YORK, Oct. 30, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that on October 29, 2024, the Company received written notice from The Nasdaq Stock Market stating that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Read more at prnewswire.com

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (2/21/2025, 8:02:56 PM)

1.73

-0.07 (-3.89%)



Find more stocks in the Stock Screener

Follow ChartMill for more